TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25772548
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg as add-on to other therapies
Study: 25772548
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg as add-on to other therapies
Study: 23369827
Drug: Ferric citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric citrate 1 g/d
Study: 23369827
Drug: Ferric citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric citrate 6 g/d
Study: 23369827
Drug: Ferric citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric citrate 8 g/d
Study: 24102165
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser treatment (control group)
Study: 1730427
Drug: Oral melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral melphalan
Study: 29748907
Drug: Alfacalcidol (VDRA)
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (VDRA) 0.25-0.5 µg once a day
Study: 29748907
Drug: Alfacalcidol (VDRA)
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (VDRA) 0.25-0.5 µg once a day + Lanthanum carbonate (LC) 250 mg once a day
Study: 24670828
Drug: Drug Eluting
Normalized name: Drug eluting stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Eluting Balloon (DEB)
Study: 22452942
Drug: Granisetron transdermal
Normalized name: Granisetron Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron transdermal system (GTDS)
Study: 8845475
Drug: Intravenous granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous granisetron
Study: 22452942
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin (active control)
Study: 16949264
Drug: Formoterol twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol twice daily (3.45% asthma exacerbations; 6 of 174 patients)
Study: 16949264
Drug: Formoterol twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol twice daily supplemented by salbutamol
Study: 9667590
Drug: Interferon-beta1b (IFN-beta1b)
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta1b (IFN-beta1b) in combination with pentoxifylline (PTX)
Study: 8537138
Drug: Cefixime 8
Normalized name: cefixime 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 8 mg/kg body weight once daily for 5 days
Study: 30508156
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of life scores during the entire treatment period
Study: 28704520
Drug: Self-affirmation exercise
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-affirmation exercise with correcting information about MMR vaccine and autism
Study: 28704520
Drug: Control passage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control passage about bird feeding with correcting information about MMR vaccine and autism
Study: 23247973
Drug: Control cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cohort receiving no drug treatment
Study: 17109685
Drug: Talpha1 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talpha1 therapy (1.6 mg, two times a week for 26 weeks)
Study: 17109685
Drug: Talpha1 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talpha1 therapy (1.6 mg, two times a week for 52 weeks)
Study: 17109685
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no specific treatment for 18 months)
Study: 14606705
Drug: Talpha1 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talpha1 therapy
Study: 11789123
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of St. John's wort extract WS 5572 daily
Study: 11789123
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of St. John's wort extract WS 5572 daily
Study: 9247843
Drug: Homoeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homoeopathic treatment (Aconitum napellus, Apis mellifica, Belladonna, Capsicum, Chamomilla, Kalium bichromicum, Lachesis, Lycopodium, Mercurius solubilis, Okoubaka, Pulsatilla, Silicea)
Study: 9247843
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (nasal drops, antibiotics, secretolytics and/or antipyretics)
Study: 19828937
Drug: Homoeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homoeopathic treatment
Study: 7967986
Drug: Daily training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily training
Study: 3583229
Drug: Aspirin (330
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (330 mg) and dipyridamole (75 mg) taken three times daily for three weeks
Study: 17177154
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta‐1a 15 micrograms once a week
Study: 17177154
Drug: No disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: No disease-modifying therapy
Study: 10972697
Drug: Epoetin alpha
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alpha to achieve hemoglobin levels of 10 g/dL
Study: 10972697
Drug: Epoetin alpha
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alpha to achieve hemoglobin levels of 13.5 g/dL
Study: 1474076
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein (LP) = 0.86 g protein.kg‐1.day‐1 for 13 days
Study: 1474076
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein (MP) = 1.40 g protein.kg‐1.day‐1 for 13 days
Study: 1474076
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein (HP) = 2.40 g protein.kg‐1.day‐1 for 13 days
Study: 21171135
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure (PE) therapy
Study: 26591355
Drug: Losartan Potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan Potassium Tablet (50 mg once per day)
Study: 18390837
Drug: Ofatumumab 300
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 300 mg
Study: 18390837
Drug: Ofatumumab 700
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 700 mg
Study: 30723894
Drug: Ofatumumab 1000
Normalized name: ofatumumab 1000 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab 1000 mg
Study: 20506254
Drug: Ofatumumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab (all doses combined)
Study: 18160461
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (25, 50, 125, 300, or 600 mg im) for 20 weeks
Study: 17063637
Drug: Gliclazide modified
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide modified release (MR) tablets (30 mg)
Study: 17063637
Drug: Commercial gliclazide
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial gliclazide standard preparation (30 mg)
Study: 14628980
Drug: Aripiprazole 15
Normalized name: aripiprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 15 mg
Study: 9243044
Drug: Isoniazid (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (300 mg/d)
Study: 9243044
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg/d)
Study: 9243044
Drug: Pyrazinamide (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrazinamide (1,500 mg/d)
Study: 8478235
Drug: Hyperthermia treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermia treatment (60 min, 1 or 2 times per week during irradiation)
Study: 31564236
Drug: Outpatient physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient physical therapy intervention including a 1-hour initial assessment and individualized treatment plans
Study: 22441448
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 1 ml betamethasone and 1 ml prilocaine on the lateral epicondyle at the point of maximum tenderness.
Study: 22441448
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of the same drug mixture with needle tip redirected and reinserted down the bone approximately 30 to 40 times without emerging from the skin, creating a hematoma.
Study: 19933822
Drug: Cushing's syndrome
Normalized name: Mifepristone 300mg Oral tablet [Cushing's Syndrome Hyperglycemia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cushing's syndrome treatment (normalization of corticosteroid excess)
Study: 19933822
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for Cushing's syndrome)
Study: 16904718
Drug: CQ 50
Normalized name: Chloroquine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQ 50 mg/kg
Study: 16904718
Drug: CQ 25
Normalized name: Chloroquine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQ 25 mg/kg
Study: 16904718
Drug: AQ 15
Normalized name: Follistim AQ 150 UNT in 0.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQ 15 mg/kg
Study: 16904718
Drug: AQ 30
Normalized name: Follistim AQ 300 UNT in 0.36 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQ 30 mg/kg
Study: 16168215
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (group B)
Study: 16168215
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (group A)
Study: 11787985
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (50 mg zinc as gluconate, orally, for 12 weeks)
Study: 28945160
Drug: Telemedicine-delivered behaviour
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine-delivered behaviour activation treatment (BAT)
Study: 28945160
Drug: Same-room behaviour
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-room behaviour activation treatment (BAT)
Study: 27059816
Drug: Dulaglutide 1.5
Normalized name: dulaglutide 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 1.5 mg/week
Study: 27059816
Drug: Dulaglutide 0.75
Normalized name: DULAGLUTIDE 0.75MG/0.5ML INJ PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 0.75 mg/week
Study: 27059816
Drug: Metformin ≥1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin ≥1500 mg/day
Study: 24063860
Drug: sorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib plus interleukin-2 (IL-2) 400 mg twice daily plus subcutaneous IL-2 4.5 million international units (MIU) five times per week for 6 weeks every 8 weeks (arm A)
Study: 21463474
Drug: Remoxy 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxy 40 mg whole (fed)
Study: 21463474
Drug: Remoxy 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxy 40 mg chewed (fed)
Study: 21463474
Drug: Oxycodone ER
Normalized name: oxycodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone ER 40 mg (crushed, fasted)
Study: 21463474
Drug: Oxycodone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone IR 40 mg (crushed, fasted)
Study: 21463474
Drug: Oxycodone ER
Normalized name: oxycodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone ER 40 mg (whole and chewed)
Study: 12927657
Drug: Amiloride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (10 mg daily)
Study: 29290068
Drug: 0.5% minoxidil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% minoxidil cream applied twice daily for 2 weeks
Study: 29290068
Drug: 2% diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% diltiazem cream applied twice daily for 2 weeks
Study: 24239790
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (cathodal tDCS + VR)
Study: 21974764
Drug: Valsartan 10-20
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan 10-20 mg
Study: 21974764
Drug: Valsartan 80-160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80-160 mg
Study: 15668554
Drug: Conventional chest
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional chest physical treatments
Study: 9517989
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (GCV) 1000 mg three times/day
Study: 9517989
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (GCV) 1000 mg three times/day (at protocol amendment)
Study: 9517989
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (GCV) for patients taking didanosine (ddI)
Study: 9517989
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (GCV) for patients not taking didanosine (ddI)
Study: 3261547
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection in the antecubital fossa
Study: 3261547
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol mixed with lignocaine
Study: 3261547
Drug: Slowing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slowing the speed of injection
Study: 24389403
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL of red wine
Study: 24389403
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL of vodka
Study: 18675399
Drug: High stress
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High stress (prior to receiving methadone dose)
Study: 18675399
Drug: Low stress
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low stress (immediately following methadone dose)
Study: 17186094
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose streptokinase (500,000 to 750,000 U)
Study: 17186094
Drug: Classical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical therapy (1.5 million U)
Study: 1680135
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage of zidovudine
Study: 1680135
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage of zidovudine
Study: 6134543
Drug: lorazepam 3
Normalized name: lorazepam 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam 3 mg
Study: 6134543
Drug: diazepam 15
Normalized name: diazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 15 mg
Study: 7793217
Drug: lorazepam 1
Normalized name: lorazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam 1 mg
Study: 30531464
Drug: Microdoses of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdoses of recombinant human erythropoietin (rHuEpo) (20‐40 IUkg) administered twice per week for 7 weeks
Study: 30531464
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice per week for 7 weeks
Study: 18053628
Drug: Modafinil treatment
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil treatment for 21 days
Study: 18053628
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 21 days
Study: 31273283
Drug: Modafinil treatment
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil treatment
Study: 15945001
Drug: Dorzolamide/Timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide/Timolol fixed combination (DTFC) 0.5%/2%
Study: 15552533
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy with antihypertensive drugs (E1)
Study: 15552533
Drug: Single diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single diet therapy (E2)
Study: 9064058
Drug: Lomefloxacin 400
Normalized name: lomefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 400 mg once daily for 3 days
Study: 9064058
Drug: Norfloxacin 800
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin 800 mg twice daily for 10 days
Study: 8341188
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose salbutamol (2.5 mg)
Study: 8341188
Drug: Variable dose
Normalized name: methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable dose salbutamol (0.1 mg/kg bodyweight)
Study: 8341188
Drug: Both preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both preparations of salbutamol
Study: 3525883
Drug: S6472 (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: S6472 (1,500 mg/day, 750 mg after breakfast and supper for 14 days)
Study: 3525883
Drug: Cefaclor (CCL)
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor (CCL) (1,500 mg/day, 500 mg after every meal for 14 days)
Study: 3525883
Drug: Amoxicillin (AMPC)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (AMPC) (2,000 mg/day, 500 mg after every meal and at bedtime for 14 days)
Study: 28849779
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.5 mg/kg over 40 min)
Study: 25622633
Drug: Compound digestive
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound digestive enzyme tablet (Bearse) plus 2 analog capsules of compound digestive enzyme thrice daily
Study: 25622633
Drug: Compound digestive
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound digestive enzyme capsule (Dages) plus 1 analog tablet of compound digestive enzyme thrice daily
Study: 25622633
Drug: Compound digestive
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound digestive enzyme tablet (Bearse)
Study: 25622633
Drug: Compound digestive
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound digestive enzyme capsule (Dages)
Study: 23246119
Drug: Topical voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical voriconazole therapy (1% voriconazole)
Study: 23246119
Drug: Intrastromal voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrastromal voriconazole (50 μg/0.1 ml)
Study: 18837860
Drug: Quetiapine (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (400-800 mg/day, twice daily)
Study: 10096260
Drug: R-verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-verapamil (120 mg)
Study: 497074
Drug: Extradural analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural analgesia (EA) with 50 or 100 mg of etidocaine without adrenaline in the supine position
Study: 497074
Drug: Extradural analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural analgesia (EA) with 50 or 100 mg of etidocaine without adrenaline in the lateral position
Study: 30387869
Drug: Single-implant mandibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-implant mandibular overdenture (SIMO)
Study: 30049849
Drug: Vasopressin V2
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin V2 receptor antagonists
Study: 30049849
Drug: Disease-modifying treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying treatments (e.g., somatostatin analogs and other novel agents)
Study: 19949136
Drug: Aspirin, 80
Normalized name: Non-Aspirin, 80 mg/0.8 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 80 mg/d for 8 weeks
Study: 19034856
Drug: ATTENTIONER therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATTENTIONER therapy
Study: 15733716
Drug: Normal hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal hospital diet plus oral nutritional supplements
Study: 14571284
Drug: Carbamazepine with
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine with honey (200 mg carbamazepine + 30 ml honey)
Study: 14571284
Drug: Carbamazepine with
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine with water (200 mg carbamazepine + water)
Study: 8618248
Drug: Extended relief
Normalized name: Midol Extended Relief
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended relief acetaminophen
Study: 8618248
Drug: Regular release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular release acetaminophen